{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee GQ"],"funding":["Michael Smith Foundation for Health Research (MSFHR)","NIAID NIH HHS","U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","Michael Smith Foundation for Health Research","U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)","Wellcome Trust","Gouvernement du Canada | Canadian Institutes of Health Research","Division of Intramural Research, National Institute of Allergy and Infectious Diseases","Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada)","Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID)"],"pagination":["5480"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11219899"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["The primary obstacle to curing HIV-1 is a reservoir of CD4+ cells that contain stably integrated provirus. Previous studies characterizing the proviral landscape, which have been predominantly conducted in males in the United States and Europe living with HIV-1 subtype B, have revealed that most proviruses that persist during antiretroviral therapy (ART) are defective. In contrast, less is known about proviral landscapes in females with non-B subtypes, which represents the largest group of individuals living with HIV-1. Here, we analyze genomic DNA from resting CD4+ T-cells from 16 female and seven male Ugandans with HIV-1 receiving suppressive ART (n = 23). We perform near-full-length proviral sequencing at limiting dilution to examine the proviral genetic landscape, yielding 607 HIV-1 su"],"journal":["Nature communications"],"pubmed_title":["HIV-1 subtype A1, D, and recombinant proviral genome landscapes during long-term suppressive therapy."],"pmcid":["PMC11219899"],"funding_grant_id":["CGS-M awards","Canada Research Chairs Program","UM1AI164565","Vanier Canada Graduate Scholarship","107752/Z/15/Z","PJT-159625","Scholar Award","UM1 AI164565","NA","R21AI150398","R21 AI150398","R01 AI162221","R01AI162221"],"pubmed_authors":["Brumme ZL","Prodger JL","Gowanlock SN","Anok A","Kityamuweesi T","Reynolds SJ","Kinloch NN","Kasule J","Buule P","Tomusange S","Quinn TC","Lee GQ","Galiwango RM","Chen Z","Copertino DC","Redd AD","Omondi FH","Jamiru S","Jones RB","Duncan MC","Khadka P"],"additional_accession":[]},"is_claimable":false,"name":"HIV-1 subtype A1, D, and recombinant proviral genome landscapes during long-term suppressive therapy.","description":"The primary obstacle to curing HIV-1 is a reservoir of CD4+ cells that contain stably integrated provirus. Previous studies characterizing the proviral landscape, which have been predominantly conducted in males in the United States and Europe living with HIV-1 subtype B, have revealed that most proviruses that persist during antiretroviral therapy (ART) are defective. In contrast, less is known about proviral landscapes in females with non-B subtypes, which represents the largest group of individuals living with HIV-1. Here, we analyze genomic DNA from resting CD4+ T-cells from 16 female and seven male Ugandans with HIV-1 receiving suppressive ART (n = 23). We perform near-full-length proviral sequencing at limiting dilution to examine the proviral genetic landscape, yielding 607 HIV-1 su","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-07-15T08:23:16.399Z","creation":"2025-04-04T12:21:09.122Z"},"accession":"S-EPMC11219899","cross_references":{"pubmed":["38956017"],"doi":["10.1038/s41467-024-48985-9"]}}